Catalyst Pharmaceuticals (CPRX) News Today → America could fall from this event (From Porter & Company) (Ad) Free CPRX Stock Alerts $16.22 +0.28 (+1.76%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 7:01 AM | americanbankingnews.comHC Wainwright Raises Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target to $26.00May 12 at 2:53 AM | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Rating Lowered to Hold at StockNews.comMay 11 at 12:17 AM | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Downgraded to "Hold" at StockNews.comStockNews.com downgraded Catalyst Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday.May 10, 2024 | markets.businessinsider.comDecoding 8 Analyst Evaluations For Catalyst PharmaceuticalsMay 10, 2024 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $26.00 at HC WainwrightHC Wainwright lifted their target price on shares of Catalyst Pharmaceuticals from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday.May 8, 2024 | msn.comCPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | sfgate.comCatalyst: Q1 Earnings SnapshotMay 8, 2024 | msn.comCatalyst Pharmaceuticals Non-GAAP EPS of $0.38 beats by $0.08, revenue of $98.44M misses by $0.33MMay 8, 2024 | globenewswire.comCatalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business UpdateMay 6, 2024 | americanbankingnews.comCatalyst Pharmaceuticals (CPRX) Set to Announce Earnings on WednesdayMay 1, 2024 | finance.yahoo.comCatalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024May 1, 2024 | marketbeat.comCatalyst Pharmaceuticals (CPRX) to Release Earnings on WednesdayCatalyst Pharmaceuticals (NASDAQ:CPRX) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=587146)April 26, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Expected to Earn Q1 2025 Earnings of $0.67 Per ShareCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Zacks Research raised their Q1 2025 earnings estimates for Catalyst Pharmaceuticals in a report released on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn $0.67 perApril 25, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. Expected to Post Q4 2025 Earnings of $0.65 Per Share (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Equities researchers at Zacks Research reduced their Q4 2025 earnings estimates for Catalyst Pharmaceuticals in a research report issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutiApril 25, 2024 | globenewswire.comSanthera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in MayApril 24, 2024 | investorplace.comDirt-Cheap Delights: 3 Discounted Stocks That Could Triple by 2026April 23, 2024 | barrons.comCatalyst Pharmaceuticals Inc.April 22, 2024 | globenewswire.comCatalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024April 21, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Has $2.61 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Allspring Global Investments Holdings LLC decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 67.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 155,234 shares of the biopharmaceuticApril 18, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stake Reduced by Cornercap Investment Counsel Inc.Cornercap Investment Counsel Inc. trimmed its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 84.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 13,387 shares of the biopharmaceutical company's stock after selling 73,786 sharApril 15, 2024 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Shares Up 3.5%Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 3.5% HigherApril 11, 2024 | insidertrades.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director David S. Tierney Sells 25,000 SharesApril 8, 2024 | msn.comSingle Catalyst Paves the Way for Efficient Drug SynthesisApril 7, 2024 | cnn.comCatalyst Pharmaceuticals, Inc.April 6, 2024 | seekingalpha.comCatalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)April 6, 2024 | marketbeat.comVanguard Group Inc. Raises Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Vanguard Group Inc. grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 2.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,046,487 shares of the biopharmaceuticalApril 5, 2024 | nasdaq.comFirst Week of May 17th Options Trading For Catalyst Pharmaceuticals (CPRX)April 2, 2024 | marketbeat.comShort Interest in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Drops By 9.9%Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 5,830,000 shares, a drop of 9.9% from the February 29th total of 6,470,000 shares. Based on an average daily volume of 1,490,000 shares, the short-interest ratio is currently 3.9 days. Approximately 5.8% of the company's shares are short sold.April 1, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of "Buy" by BrokeragesCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has received a consensus recommendation of "Buy" from the five research firms that are currently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 12-monthMarch 31, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Down 9.9% in MarchCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 5,830,000 shares, a decrease of 9.9% from the February 29th total of 6,470,000 shares. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is presently 3.9 days. Approximately 5.8% of the shares of the stock are sold short.March 30, 2024 | insidertrades.comBrian Elsbernd Sells 25,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) StockMarch 29, 2024 | marketbeat.comBrokers Set Expectations for Catalyst Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Analysts at Cantor Fitzgerald lowered their FY2024 earnings per share estimates for Catalyst Pharmaceuticals in a research report issued to clients and investors on Thursday, March 28th. Cantor Fitzgerald analyst C. Duncan now expects tMarch 28, 2024 | finance.yahoo.comInsider Sell: Chief Compliance/Legal Officer Brian Elsbernd Sells 25,000 Shares of Catalyst ...March 28, 2024 | marketbeat.comInsider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells 25,000 Shares of StockCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Brian Elsbernd sold 25,000 shares of the stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total value of $411,000.00. Following the transaction, the insider now directly owns 124,433 shares of the company's stock, valued at $2,045,678.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 28, 2024 | globenewswire.comCatalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness DayMarch 27, 2024 | markets.businessinsider.comDecoding 7 Analyst Evaluations For Catalyst PharmaceuticalsMarch 27, 2024 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Earns Outperform Rating from OppenheimerOppenheimer reiterated an "outperform" rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a research note on Wednesday.March 27, 2024 | globenewswire.comCatalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy SymposiumMarch 27, 2024 | investorplace.com3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch ListMarch 24, 2024 | marketbeat.comAmerican Century Companies Inc. Raises Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)American Century Companies Inc. lifted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 20.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 899,478 shares of the biopharmaceMarch 22, 2024 | finance.yahoo.comInvestors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three yearsMarch 22, 2024 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Receives "Overweight" Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and set a $34.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday.March 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 18, 2024 | marketbeat.comCatalyst Pharmaceuticals' (CPRX) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and issued a $34.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday.March 16, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Sees Large Increase in Short InterestCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) was the target of a significant increase in short interest during the month of February. As of February 29th, there was short interest totalling 6,470,000 shares, an increase of 14.1% from the February 14th total of 5,670,000 shares. Approximately 6.5% of the shares of the company are sold short. Based on an average trading volume of 1,520,000 shares, the short-interest ratio is presently 4.3 days.March 16, 2024 | marketbeat.comHudson Bay Capital Management LP Acquires 100,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Hudson Bay Capital Management LP raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 50.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 300,000 shares of the biopharmaceutMarch 15, 2024 | finance.yahoo.comCPRX Apr 2024 12.500 callMarch 15, 2024 | finance.yahoo.comCPRX Apr 2024 17.500 putMarch 14, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: REPRO-MED Systems (KRMD), Catalyst Pharma (CPRX)March 14, 2024 | finance.yahoo.comCPRX Apr 2024 20.000 put Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Healthcare Takes A Big Step Forward With The Help Of AI (Ad)The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+. Click here to see why this small company is trusted by the Mayo Clinic CPRX Media Mentions By Week CPRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CPRX News Sentiment▼0.340.57▲Average Medical News Sentiment CPRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CPRX Articles This Week▼154▲CPRX Articles Average Week Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HRMY News EVO News GPCR News SDGR News SUPN News AGIO News GLPG News ZLAB News AVDL News NAMS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CPRX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportGuard Against the Coming Financial UpheavalPorter & CompanyDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsThis 1 Biotech Stock has been shocking the marketsHuge AlertsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
